Mesoblast Limited (NASDAQ: MESO) has inked a collaboration agreement with Novartis for the development, making, and commercialization of remestemcel-L. The firms have reported that after joining forces their main focus is to produce the cure for Acute Respiratory distress syndrome (ARDS) and COVID-19. Through